Informations générales (source: ClinicalTrials.gov)
Prevalence of Atrial Fibrillation in Cryptogenic Stroke With Patent Foramen Ovale Closure (PFO-AF) Study (PFO-AF)
Observational
Centre Hospitalier Universitaire de Besancon (Voir sur ClinicalTrials)
juillet 2021
décembre 2025
29 juin 2024
This study aims to assess the incidence of atrial fibrillation (AF), documented using
data recorded by an implantable Holter monitoring device (Reveal Linq, Medtronic) within
2 years after percutaneous closure of patent foramen ovale for cryptogenic stroke.
Etablissements
| Les établissements sans correspondance certaine dans le répertoire FINESS dont les données sont issues de ClinicalTrials.gov Origine et niveau de fiabilité des données | |||||
|---|---|---|---|---|---|
| CHU Dijon - Dijon - France | Contact (sur clinicalTrials) | ||||
| CHU Grenoble - Grenoble - France | Contact (sur clinicalTrials) | ||||
| CHU Lyon - Hôpital Louis Pradel - Bron - France | Contact (sur clinicalTrials) | ||||
| University Hospital Besancon - 25000 - Besançon - France | Contact (sur clinicalTrials) | ||||
Critères
Tous
Inclusion Criteria:
- Adult patients (aged >18 years)
- with an indication for percutaneous closure of PFO due to cryptogenic stroke, with
indication validated by a cardio-neurological team.
- patients must provide written informed consent
- patients must be affiliated to a social security regime or be a beneficiary thereof.
- Adult patients (aged >18 years)
- with an indication for percutaneous closure of PFO due to cryptogenic stroke, with
indication validated by a cardio-neurological team.
- patients must provide written informed consent
- patients must be affiliated to a social security regime or be a beneficiary thereof.
- Patients under legal protection
- Patients not affiliated to any social security regime
- Patients within the exclusion period of another clinical trial as per the national
registry of research volunteers